Literature DB >> 26142051

Poor prognosis despite aggressive treatment in adults with intramedullary spinal cord glioblastoma.

Ann Liu1, Eric W Sankey1, Chetan Bettegowda2, Peter C Burger3, George I Jallo1, Mari L Groves1.   

Abstract

We report our institution's experience with adult patients who underwent surgery for intramedullary spinal cord glioblastoma. Spine involvement of glioblastoma is rare, representing 7.5% of all intramedullary gliomas and 1-3% of all spinal cord tumors. We performed a retrospective review of five male patients with intramedullary spinal cord glioblastoma who underwent surgical resection from 1990 to 2014. Demographic, operative, and postoperative factors were recorded. The median age at treatment was 31 years (range: 18-61) and all men presented with motor or sensory dysfunction. Two had prior surgical resection of an intramedullary World Health Organization Grade III anaplastic astrocytoma lesion with adjuvant chemoradiation. All tumors were present in the cervical (n=2; 40%) or thoracic (n=3; 60%) spine, spanning a median of three levels (range: 2-4). Gross total resection was achieved in three men (60%), and there were no intraoperative mortalities or complications. Although one had improvement in his neurological status postoperatively, all five men died with a median time to death of 20 months (range: 2-31). Adult intramedullary spinal cord glioblastoma is rare, and despite aggressive treatment, prognosis is poor, with a median survival in our series of only 20 months. New treatment strategies are necessary to improve survival in this patient population.
Copyright © 2015 Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  Adult; Glioblastoma; Intramedullary; Oncology; Spine

Mesh:

Year:  2015        PMID: 26142051     DOI: 10.1016/j.jocn.2015.05.008

Source DB:  PubMed          Journal:  J Clin Neurosci        ISSN: 0967-5868            Impact factor:   1.961


  5 in total

1.  Impact of surgery and radiation therapy on spinal high-grade gliomas: a population-based study.

Authors:  Jiang Liu; Minghui Zheng; Wuyang Yang; Sheng-Fu L Lo; Judy Huang
Journal:  J Neurooncol       Date:  2018-05-23       Impact factor: 4.130

Review 2.  Updates in the management of intradural spinal cord tumors: a radiation oncology focus.

Authors:  Rupesh Kotecha; Minesh P Mehta; Eric L Chang; Paul D Brown; John H Suh; Simon S Lo; Sunit Das; Haider H Samawi; Julia Keith; James Perry; Arjun Sahgal
Journal:  Neuro Oncol       Date:  2019-06-10       Impact factor: 12.300

3.  Antimicrobial Peptide TP4 Induces ROS-Mediated Necrosis by Triggering Mitochondrial Dysfunction in Wild-Type and Mutant p53 Glioblastoma Cells.

Authors:  Bor-Chyuan Su; Chieh-Yu Pan; Jyh-Yih Chen
Journal:  Cancers (Basel)       Date:  2019-02-01       Impact factor: 6.639

Review 4.  Therapeutic Approaches in Adult Primary Spinal Cord Astrocytoma: A Systematic Review.

Authors:  Elena Anghileri; Morgan Broggi; Elio Mazzapicchi; Mariangela Farinotti; Andrea Botturi; Irene Tramacere; Marcello Marchetti
Journal:  Cancers (Basel)       Date:  2022-03-02       Impact factor: 6.639

5.  Clinical outcomes and a therapeutic indication of intramedullary spinal cord astrocytoma.

Authors:  Narihito Nagoshi; Osahiko Tsuji; Satoshi Suzuki; Satoshi Nori; Mitsuru Yagi; Eijiro Okada; Hajime Okita; Nobuyuki Fujita; Ken Ishii; Morio Matsumoto; Masaya Nakamura; Kota Watanabe
Journal:  Spinal Cord       Date:  2021-07-26       Impact factor: 2.772

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.